Pathology-guided multimodal transformer predicts postoperative survival benefit from adjuvant chemotherapy in glioma: from DNA damage repair to immune characterization
This model identifies patients unlikely to benefit from standard TMZ chemotherapy, providing a tool for postoperative personalized treatment stratification and optimization of therapeutic strategies in HGGs.